NL-OMON51511尚未招募2 期
Anti-COVID19 VaccinaTion AKS-452X BOOSTER Study (ACT-BOOSTER study) - ACT-BOOSTER study
Akston Biosciences Corporation0 个研究点目标入组 222 人开始时间: 待定最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 222
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •- Age 18-85 years (extremes included), males and females.
- •- Body mass index (BMI) between 19.0 and 30.0 kg/m2, inclusive
- •- General good health, without significant medical illness, as determined via
- •physical exam findings, or vital signs
- •- No clinically significant laboratory abnormalities as determined by the
- •investigator
- •Note: one retest of lab tests is allowed within the screening window
- •- Informed Consent Form signed voluntarily before any study-related procedure
- •is performed, indicating that the subject understands the purpose and
- •procedures required for the study and is willing to participate in the study
- •- Willing to adhere to the prohibitions and restrictions specified in this
- •- All participants must have received a completed (registered) vaccine or
- •booster at least three months before inclusion in this study (i.e. Pfizer
- •[Comirnaty], Moderna [Spikevax], Janssen [Ad26.COV2.S], AstraZeneca
- •[Vaxzevria]).
- •- Negative hepatitis panel (including hepatitis B surface Ag and anti-hepatitis
- •C virus Abs) and negative human immunodeficiency virus Ab and Ag screens at
- •- Female subjects should fulfil one of the following criteria:
- •o At least 1 year post-menopausal (amenorrhea >12 months)
- •o Surgically sterile (bilateral oophorectomy, hysterectomy, or tubal ligation);
- •o Will use adequate forms of contraceptives from screening to discharge.
- •- Female subjects of childbearing potential and male subjects who are sexually
- •active with a female partner of childbearing potential must agree to the use of
- •an effective method of birth control from screening to discharge
- •o Note: medically acceptable methods of contraception that may be used by the
- •subject and/or partner include combined oral contraceptive, contraceptive
- •vaginal ring, contraceptive injection, intrauterine device, etonogestrel
- •implant, double barrier, sterilization and vasectomy
- •- Female subject has a negative pregnancy test at screening and upon check-in
- •at the clinical site.
- •o Note: pregnancy testing will consist of a serum pregnancy test at screening
- •and urine pregnancy tests at the dosing visit, in all women.
排除标准
- •- Pregnant or breast-feeding females
- •- Evidence of clinically significant neurologic, cardiac, pulmonary, hepatic,
- •hematologic, rheumatologic, endocrine, autoimmune, or renal disease
- •- Any laboratory test which is abnormal, and which is deemed by the
- •Investigator(s) to be clinically significant
- •- Behavioral or cognitive impairment or psychiatric disease that in the opinion
- •of the investigator affects the ability of the subject to understand and
- •cooperate with the study protocol
- •- Current alcohol/illicit drug/nicotine abuse or addiction: history or evidence
- •of current drug use or addiction (positive drug screen for amphetamines,
- •barbiturates, benzodiazepines, cannabinoids, cocaine, or opiates) or signs of
- •excessive use of alcohol at screening and at day 0.
- •- Presence of any febrile illness (T > = 38.0°C or lab confirmed viral disease
- •(PCR)) or symptoms suggestive of a viral respiratory infection within 1 weeks
- •prior to vaccination. Participants will be screened for SARS-Cov-2 with an
- •EUA-approved PCR test at screening, and at day 0.
- •- Use of corticosteroids (excluding topical preparations for cutaneous or nasal
- •use) or use of immunosuppressive drugs within 30 days before inoculation
- •- A history of anaphylaxis, history of allergic reaction to vaccine, known
- •allergy to one of the components in AKS-452X. Mild allergies without
- •angio-edema or treatment need can be included if deemed not to be of clinical
- •significance (including but not limited to allergy to animals or mild seasonal
- •- A history of asthma within the past 10 years, or a current diagnosis of
- •asthma or reactive airway disease associated with exercise
- •- Receipt of blood or blood-derived products (including immunoglobulin) within
- •6 months prior to vaccination.
- •- Receipt of another investigational agent within 30 days or 5 times the
- •product half-life (whichever is longest) prior to vaccination
- •- Deprived of freedom by an administrative or court order or in an emergency
- •- Any condition that in the opinion of the principal investigator (PI) would
- •jeopardize the safety or rights of a person participating in the trial or would
- •render the person unable to comply with the protocol.
研究者
相似试验
进行中（未招募）
1 期
Phase 2 Booster vaccination study against COVID-19COVID-19MedDRA version: 23.1Level: LLTClassification code 10084465Term: COVID-19 vaccinationSystem Organ Class: 100000004865EUCTR2021-005509-28-NLAkston Biosciences Corporation600
进行中（未招募）
1 期
Vaccination phase I/II study against COVID-19EUCTR2020-005997-82-NLMCG176
Unknown
2 期
Anti-COVID19 VaccinaTion AKS-452 BOOSTER (ACT-BOOSTER Study)COVID-19NCT05124483University Medical Center Groningen600
已完成
1 期
Anti-COVID19 AKS-452 Fusion Protein Vaccine - ACT StudyCovid19NCT04681092University Medical Center Groningen112
尚未招募
不适用
COBRA re-KAI study: COVID-19 vaccination in patients with reduced B-cell and T-cell immunity: response after re-vaccination of a kaleidoscopic group of hematological patients: what*s the impact?Vaccination responsevaccine effectiveness100188491002766510047438NL-OMON56570Amsterdam UMC250